Journal Mobile Options
Table of Contents
Vol. 57, No. 1-2, 2008
Issue release date: June 2008

Association of Tumor Necrosis Factor –308G/A Promoter Polymorphism with Schizophrenia and Bipolar Affective Disorder in a Polish Population

Czerski P.M. · Rybakowski F. · Kapelski P. · Rybakowski J.K. · Dmitrzak-Węglarz M. · Leszczyńska-Rodziewicz A. · Słopień A. · Skibińska M. · Kaczmarkiewicz-Fass M. · Hauser J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: Schizophrenia (SCH) and bipolar affective disorder (BPAD) are complex disorders with significant participation of genetic risk factors. Several lines of evidence point to the role of shared neurobiological mechanisms and common genetic background in SCH and BPAD. Immune disturbances have been suggested as contributing factor in the pathogenesis of both SCH and BPAD. The gene coding cytokine tumor necrosis factor (TNF) has been the object of a number of association studies in SCH, with ambiguous results. Only 3 such studies were performed in BPAD. The aim of our study was to perform a case-control association analysis of the TNF –308G/A polymorphism in a Polish sample of patients with SCH, BPAD and healthy controls. Methods: We genotyped the TNF –308G/A polymorphism (rs1800629) by PCR-RFLP in 348 patients with SCH, 361 patients with BPAD and in 351 controls. Results: We observed an association of the –308G allele with both SCH (p = 0.008) and BPAD (p = 0.039), and also with a positive family history in patients with SCH (p = 0.048) and BPAD (p = 0.027). For TNF genotypes, the association was only seen in SCH (p = 0.018). Conclusions: Our results may point to an association of the TNF –308G allele and –308G/G genotype with both SCH and BPAD, and to a relationship of the –308G allele with the risk of SCH and BPAD in patients with a positive family history. TNF could be potentially a susceptibility gene, shared between SCH and BPAD. Complex TNF gene studies – based on multiple single-nucleotide polymorphisms and involving haplotype analysis – are necessary for the clarification of currently contradictory findings.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Murray RM, Sham P, Van Os J, Zanelli J, Cannon M, McDonald C: A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 2004;71:405–416.
  2. Craddock N, O’Donovan MC, Owen MJ: The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet 2005;42:193–204.
  3. Craddock N, Owen MJ: Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. World Psychiatry 2007;6:20–27.

    External Resources

  4. van Os J, Jones P, Lewis G, Wadsworth M, Murray R: Developmental precursors of affective illness in a general population birth cohort. Arch Gen Psychiatry 1997;54:625–631.
  5. Blumberg HP, Kaufman J, Martin A, Charney DS, Krystal JH, Peterson BS: Significance of adolescent neurodevelopment for the neural circuitry of bipolar disorder. Ann NY Acad Sci 2004;1021:376–383.
  6. Brambilla P, Glahn DC, Balestrieri M, Soares JC: Magnetic resonance findings in bipolar disorder. Psychiatr Clin North Am 2005;28:443–467.
  7. Benes FM, Matzilevich D, Burke RE, Walsh J: The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 2006;11:241–251.
  8. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF: Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006;81:47–63.
  9. Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN: The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry 2006;11:47–55.
  10. O’Brien SM, Scully P, Scott LV, Dinan TG: Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006;90:263–267.
  11. Debnath M, Chaudhuri TK: The role of HLA-G in cytokine homeostasis during early pregnancy complicated with maternal infections: a novel etiopathological approach to the neurodevelopmental understanding of schizophrenia. Med Hypotheses 2006;66:286–293.
  12. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ: Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol 2004;150:116–122.
  13. Kim YK, Jung HG, Myint AM, Kim H, Park SH: Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007;104:91–95.
  14. Na KS, Kim YK: Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 2007;56:55–63.
  15. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801–808.
  16. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E: Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007;7:46.
  17. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201–217.
  18. O’Brien SM, Scott LV, Dinan TG: Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004;19:397–403.
  19. Cacquevel M, Lebeurrier N, Cheenne S, Vivien D: Cytokines in neuroinflammation and Alzheimer’s disease. Curr Drug Targets 2004;5:529–534.
  20. Munoz-Fernandez MA, Fresno M: The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 1998;56:307–340.
  21. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP: Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998;33:251–254.
  22. Wright P, Donaldson PT, Underhill JA, Choudhuri K, Doherty DG, Murray RM: Genetic association of the HLA DRB1 gene locus on chromosome 6p21.3 with schizophrenia. Am J Psychiatry 1996;153:1530–1533.
  23. Schwab SG, Hallmayer J, Freimann J, Lerer B, Albus M, Borrmann-Hassenbach M, Segman RH, Trixler M, Rietschel M, Maier W, Wildenauer DB: Investigation of linkage and association/linkage disequilibrium of HLA A-, DQA1-, DQB1-, and DRB1-alleles in 69 sib-pair- and 89 trio-families with schizophrenia. Am J Med Genet 2002;114:315–320.
  24. Arolt V, Lencer R, Purmann S, Schurmann M, Muller-Myhsok B, Krecker K, Schwinger E: Testing for linkage of eye tracking dysfunction and schizophrenia to markers on chromosomes 6, 8, 9, 20, and 22 in families multiply affected with schizophrenia. Am J Med Genet 1999;88:603–606.
  25. Bogacki PA, Borkowska A, Wojtanowska-Bogacka M, Rybakowski JK: Relationship between class I and II HLA antigens in schizophrenia and eye movement disturbances: a preliminary study. Neuropsychobiology 2005;51:204–210.
  26. Monteleone P, Fabrazzo M, Tortorella A, Maj M: Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 1997;71:11–17.
  27. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, Stefanis CN: Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001;47:13–25.
  28. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM: A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 1997;26:227–233.
  29. Paterson GJ, Ohashi Y, Reynolds GP, Pratt J, Morris BJ: Selective increases in the cytokine, TNF-α, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. J Psychopharmacol 2006;20:636–642.
  30. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, Pollmacher T: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33:407–418.
  31. Baker I, Masserano J, Wyatt RJ: Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 1996;20:199–203.
  32. Kaminska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszen M: Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 2001;49:439–445.
  33. Schattner A, Cori Y, Hahn T, Sirota P: No evidence for autoimmunity in schizophrenia. J Autoimmun 1996;9:661–666.
  34. Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M: Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 2001;10:109–115.
  35. Kowalski J, Blada P, Kucia K, Madej A, Herman ZS: Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 2001;50:169–175.
  36. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M: Association between –G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 2001;6:79–82.
  37. Hanninen K, Katila H, Rontu R, Mattila KM, Hurme M, Lehtimaki T: Tumor necrosis factor-alpha –G308A polymorphism in schizophrenia in a Finnish population. Neurosci Lett 2005;385:76–81.
  38. Meira-Lima IV, Pereira AC, Mota GF, Floriano M, Araujo F, Mansur AJ, Krieger JE, Vallada H: Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: further support for an association with schizophrenia. Mol Psychiatry 2003;8:718–720.
  39. Schwab SG, Mondabon S, Knapp M, Albus M, Hallmayer J, Borrmann-Hassenbach M, Trixler M, Gross M, Schulze TG, Rietschel M, Lerer B, Maier W, Wildenauer DB: Association of tumor necrosis factor alpha gene –G308A polymorphism with schizophrenia. Schizophr Res 2003;65:19–25.
  40. Tan EC, Chong SA, Tan CH, Teo YY, Peng K, Mahendran R: Tumor necrosis factor-alpha gene promoter polymorphisms in chronic schizophrenia. Biol Psychiatry 2003;54:1205–1211.
  41. Morar B, Schwab SG, Albus M, Maier W, Lerer B, Wildenauer DB: Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007;144:318–324.
  42. Duan S, Xu Y, Chen W, Liu Z, Guo T, Gao J, Bian L, Zhen Y, Li X, Zhang X, Pan Y, Gu N, Feng G, He L: No association between the promoter variants of tumor necrosis factor alpha (TNF-alpha) and schizophrenia in Chinese Han population. Neurosci Lett 2004;366:139–143.
  43. Pae CU, Serretti A, Artioli P, Kim TS, Kim JJ, Lee CU, Lee SJ, Paik IH, Lee C: Interaction analysis between 5-HTTLPR and TNFA –238/–308 polymorphisms in schizophrenia. J Neural Transm 2006;113:887–897.
  44. Handoko HY, Nancarrow DJ, Hayward NK, Ohaeri JU, Aghanwa H, McGrath JJ, Levinson DF, Johns C, Walters MK, Nertney DA, Srinivasan TN, Thara R, Mowry BJ: Tumor necrosis factor haplotype analysis amongst schizophrenia probands from four distinct populations in the Asia-Pacific region. Am J Med Genet B Neuropsychiatr Genet 2003;121:1–6.

    External Resources

  45. Hashimoto R, Yoshida M, Ozaki N, Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Tatsumi M, Kamijima K, Kunugi H: Association analysis of the –308G → A promoter polymorphism of the tumor necrosis factor alpha (TNF-alpha) gene in Japanese patients with schizophrenia. J Neural Transm 2004;111:217–221.
  46. Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, Lehtimaki T: Interaction of tumor necrosis alpha –G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005;255:279–283.
  47. Pae CU, Chae JH, Bahk WM, Han H, Jun TY, Kim KS, Kwon YS, Serretti A: Tumor necrosis factor-alpha gene polymorphism at position –308 and schizophrenia in the Korean population. Psychiatry Clin Neurosci 2003;57:399–403.
  48. Riedel M, Kronig H, Schwarz MJ, Engel RR, Kuhn KU, Sikorski C, Sokullu S, Ackenheil M, Moller HJ, Muller N: No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 2002;252:232–234.
  49. Shirts BH, Bamne M, Kim JJ, Talkowski M, Wood J, Yolken R, Nimgaonkar VL: A comprehensive genetic association and functional study of TNF in schizophrenia risk. Schizophr Res 2006;83:7–13.
  50. Tsai SJ, Hong CJ, Yu YW, Lin CH, Liu LL: No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophr Res 2003;65:27–32.
  51. Watanabe Y, Muratake T, Kaneko N, Fukui N, Nara Y, Someya T: No association between the tumor necrosis factor-alpha gene promoter polymorphisms and schizophrenia in a Japanese population. Psychiatry Res 2007;153:1–6.
  52. Zai G, Muller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, Kennedy JL: Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 2006;188:171–182.
  53. Sacchetti E, Bocchio-Chiavetto L, Valsecchi P, Scassellati C, Pasqualetti P, Bonvicini C, Corsini P, Rossi G, Cesana BM, Barlati S, Gennarelli M: –G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study. Brain Behav Immun 2007;21:450–457.
  54. Pae CU, Lee KU, Han H, Serretti A, Jun TY: Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Res 2004;125:65–68.
  55. Middle F, Jones I, Robertson E, Lendon C, Craddock N: Tumour necrosis factor alpha and bipolar affective puerperal psychosis. Psychiatr Genet 2000;10:195–198.
  56. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, American Psychiatric Press, 1996.
  57. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
  58. Wilson AG, di Giovine FS, Blakemore AI, Duff GW: Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992;1:353.
  59. Hohoff C, Tidow N, Stoll M, Rust S, Lencer R, Purmann S, Schwinger E, Brandt B, Deckert J, Arolt V: Tumor necrosis factor alpha polymorphisms in schizophrenia families characterised for the endophenotype eye tracking dysfunction (ETD). Abstracts for the 12th World Congress of Psychiatric Genetics. Dublin, Ireland, 9–13 October 2004. Am J Med Genet B Neuropsychiatr Genet 2004;130:53.
  60. Saviouk V, Chow EW, Bassett AS, Brzustowicz LM: Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44. Mol Psychiatry 2005;10:375–383.
  61. Craddock N, Owen MJ: The beginning of the end for the Kraepelinian dichotomy. Br J Psychiatry 2005;186:364–366.
  62. Zhang XY, Haile CN, Tan YL, Zuo LJ, Yang BZ, Cao LY, Zhou DF: Tumour necrosis factor alpha polymorphism (–1031T/C) is associated with age of onset of schizophrenia. Mol Psychiatry 2005;10:897–899.
  63. Abraham LJ, Kroeger KM: Impact of the –308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999;66:562–566.
  64. Kroeger KM, Steer JH, Joyce DA, Abraham LJ: Effects of stimulus and cell type on the expression of the –308 tumour necrosis factor promoter polymorphism. Cytokine 2000;12:110–119.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50